-
-
-
-
-
-
-
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
-
-
-
-
-
-
-
BTIG on Praxis Precision Medicines Inc. (PRAX): NDA acceptance offers clean regulatory setup for approval
-
-
-
-
-
-
15,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

